Together we share one goal: to accelerate the development and manufacture of safe advanced therapies.
Together we cure®.
We all know that some serious innovation is needed to get cell and gene therapies to the patients who need them. This Innovation cannot happen without collaboration. The problems our industry faces are too complex and the stakes are too high for us to work alone.
For more than a decade, Akron Bio has worked closely with academic and industry partners to establish standards, reduce cost of goods, and develop safer, commercial-ready materials.
We’re better when we work together. Its why we believe in building strong and lasting partnerships.
Here are some of our ongoing collaborations. Get in touch with us if you have big ideas to advance the cell and gene therapy industry through manufacturing innovation.
In January of 2021, Akron signed an exclusive global agreement to manufacture virus inactivated Human AB Serum for the cell and gene therapy market using Octaplas®, Octapharma’s pooled, solvent-detergent treated human plasma. Leveraging pharmaceutically licensed, virus inactivated pooled plasma as a starting material, this product offers greater batch-to-batch consistency and an excellent safety profile. Learn more about our exclusive partnership with Octapharma.
Akron and Cytiva have established a partnership to onboard the FlexFactory, Cytiva’s flexible, single-use manufacturing platform to enable Akron Biotech to manufacture cGMP plasmid DNA (pDNA), a critical component in the development of advanced therapies and vaccines. When Akron’s cGMP plasmid capabilities come online in Q4 2021, it will be the industry’s first FlexFactory installation dedicated to the manufacture of pDNA. Learn more about our platform and how we can use it to support your plasmid manufacturing needs.
To meet the challenge posed by Covid-19 and other respiratory viruses that may yet emerge, we will need a variety of therapeutic options alongside the growing portfolio of vaccines. To enable the next generation of treatments targeting respiratory diseases, Akron has partnered with Synairgen, to support the manufacture of the company’s wholly-owned inhaled interferon beta (IFN-beta) therapeutic candidate. Akron supports clinical development and future commercialization through the manufacture and delivery of IFN-beta.
Established approaches to cell and gene therapy manufacturing are costly and complex. There are significant opportunities to reduce cost and mitigate risk through supply chain and process optimization. Akron is collaborating with Georgia Tech and BioFabUSA to develop a decision support system that enables therapeutic developers to optimize capacity planning and supply chain configuration in silico through a digital twin framework, thereby streamlining complex operations and enabling commercial success.
The cryopreservation of tissues and other multicellular constructs is one of the principal challenges associated with delivering engineered tissues. We are working closely with Dr. Marsha Rolle, Associate Professor of Biomedical Engineering at Worcester Polytechnic Institute to advance a novel DMSO-free cryoprotectant that promises to improve therapeutic delivery with the support of BioFabUSA. This product now has a Master File in place with FDA to facilitate regulatory submissions. Check out Dr. Rolle’s interview with ARMI | BioFabUSA.